An interventional study of surgery in Prostate Cancer (Adenocarcinoma), Prostate Cancer (Post Prostatectomy) and Prostate Cancer Surgery, sponsored by East and North Hertfordshire NHS Trust. Recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by East and North Hertfordshire NHS Trust · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 486 studies in Prostatic Neoplasms with a site in United Kingdom — 91 open to participants now, 158 under way, 46 of them phase 3. Prostatic Neoplasms · United Kingdom.
Among the 486 studies in Prostatic Neoplasms with a site in United Kingdom, this one is the 240th largest by planned enrollment of the 393 interventional ones that give a count, is one of 25 that started in 2025, is one of 80 with no phase, reaches primary completion later than 39 of the 157 other live ones, and was the 453rd registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →91 of the 486 studies in Prostatic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+ · Men only
AstraZeneca · Sites in United Kingdom, United States, Austria and 18 more countries
Ages 18+ · Men only
University College, London · Sites in United Kingdom
Ages 18+ · Men only
University College, London · Sites in United Kingdom
Gold Standard Phantoms · Sites in United Kingdom
Ages 18+ · Men only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
486 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 99 · Phase 2 127 · Phase 3 137 · Phase 4 8
First in 1992; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 164 across the 393 interventional studies, 300 across the 88 observational. Of the 270 that completed or were terminated, 116 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 486 have an industry lead sponsor. The 10 most frequent:
East and North Hertfordshire NHS Trust is the lead sponsor of 38 studies on the registry; 20 are open to participants now.
East and North Hertfordshire NHS Trust has 4 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
37 of the studies in Prostatic Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Add all 37 to your calendar (.ics) → With an account.
Among the 486 studies in Prostatic Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the removal of prostate cancers. The data collected will inform methodologies for future, larger, multi-center trials investigating pain in patients undergoing prostate cancer surgery.
A robotic prostatectomy is a commonly performed surgery used to treat prostate cancer by removing the prostate gland. In order to perform the procedure, the surgeon must 'inflate' (technical term pneumoperitoneum) the patients abdomen with carbon dioxide gas using a device called an insufflator. Adequate 'inflation' of the abdomen ensures the surgeon can clearly visualise the prostate. Unfortunately, higher pressures of abdominal 'inflation' are a large contributor to intra and post-operative pain in patients having prostatectomies. The type of insufflator device used to maintain inflation pressures in the abdomen are thought to be a variable contributing to differing levels of intra and post-operative pain. Therefore, the purpose of this trial is to compare intra and post-operative pain when using two different insufflator devices when performing robotic prostatectomies. Both insufflators are already commonly used across multiple NHS Trusts.
40 patients awaiting a robotic prostatectomy at the urology department at the Lister hospital, Stevenage, will be randomised to use either the Conventional Insufflator System (CIS) {Stryker PneumoClear Insufflator} or the AIRSEAL® Insufflation System (AIS) to 'inflate' their abdomens during their prostatectomies. Data relating to various intra and post-operative outcomes will be collected in the 30 days following the patient's operation. Outcomes include levels of intra and post-operative pain, medication use, procedure time, recovery room time, length of hospital stay, post operative nausea and vomiting and adverse events. This data can be analysed to identify trends in differences in outcomes between the AIS and CIS insufflators.
An amendment has been approved to recruit an additional 60 participants, total overall recruitment is 100.
In this trial, 100 patients undergoing robotic prostatectomies will be randomised to have either the AIRSEAL® Insufflation System (AIS) or the Stryker PneumoClear Insufflator devices used to maintain pneumoperitoneum during surgery. Data relating to intra-operative and post-operative pain will be collected. This data will be used to identify any differences in outcomes between the two arms of the trial.
The main aim of this feasibility study will be to inform the feasibility and design of a subsequent definitive full-scale trial. The feasibility trial will collect data about recruitment, study conduct, and assessment methods. The objectives of the feasibility are to
The subsequent large scale, multi-center trial following this feasibility trial will focus on severity of pain during and immediately after surgery in the recovery room and then by 6-hour increments, measured by a 0 - 10 Numeric Rating Scale (NRS) and a PMD-200 nociception non-invasive monitor as the primary outcome
Secondary outcomes include:
Pre-Operative
Intra-operative
Post-Operative During hospital discharge, all subjects will be evaluated for incidence and severity of pain using a 0-10 numeric rating scale (NRS) and records of medication use and a PMD-200 monitor. These data will be captured in the Case Report Forms.
Recovery room:
Discharge:
Classification, including 30-day mortality
All Adverse Events (intra-operative and post-operative through 30 days):
Patients under the care of the urology department at the Lister Hospital, Stevenage will be listed in clinic for a robotic prostatectomy. If patients meet the eligibility criteria for the trial, they will be approached and informed of the RALP clinical trial during their clinic consultation, by a member of the clinical team (likely a urological consultant).
Patients will be provided with a patient information sheet informing them of the aims and methodology of the trial. Members of the research department will be able to answer any outstanding questions patients might have.
Written informed consent will be obtained from eligible patients (n=40) willing to participate in the trial. If patients consent, their GP will subsequently be written to and informed of their involvement in the trial.
Pre-Operative data collection:
Within 30 days of a subject's scheduled procedure, members of the research department at Lister hospital will obtain a medical history and record the subject's demographic (age, race, sex and date of birth) and baseline information (height, weight, and systolic/diastolic blood pressure). Within 30 days prior to the planned procedure date, obtain serum blood tests per standard of care. These will typically include:
Preoperative Randomization:
Randomization will be done electronically via a database which is facilitated by the University of Hertfordshire. Patients will be randomized 1:1 to either AIS (at 8 mmHg) or Stryker PneumoClear Insufflator Arm 1: AIRSEAL® Insufflation System (AIS) - 8 mmHg Arm 2: Stryker PneumoClear Insufflator - 8 mmHg.
Methods and Procedure:
Patients will undergo their robotic assisted prostatectomy with the use of either the AIRSEAL® Insufflation System (AIS) or Stryker PneumoClear Insufflator depending on which arm of the trial they have been randomized to. Patients will be blinded to the intervention (AIRSEAL® Insufflation System (AIS) or Stryker PneumoClear Insufflator). Both systems are commonly used devices across many NHS trusts and there is currently no evidence comparing patient outcomes between use of the two devices.
This study will be conducted at one site by one surgeon performing 40 total procedures. Study subjects will be prepared for surgery per standard institutional policy and practice. Standard operative procedures will be followed.
Case Report Forms will be also be used to collect data relating to pre-operative, intra-operative and post-operative outcomes. This data will relate to outcomes such as intra-operative pain, post operative pain scores, medication use, duration of hospital stay, presence of nausea or vomiting etc...
The final patient follow up will be in a clinic appointment 30 days following their operation. Ongoing post-operative outcomes will be assessed (pain scores, medication use, adverse events etc...).
Data will be inputted on the database which is subsequently processed and statistically analysed and reviewed. Differences in outcomes between the two arms of the trial may be identified.
Once the aforementioned data has been processed and reviewed, results may be published and also distributed to those trial participants who wished to receive ongoing information and results from the trial.
The outcomes of this research will be used to inform future research such as a full scale trial with a larger number of patients and larger volume of data
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measuring patient's pain during and after a robotic prostatectomy using the Stryker PneumoClear insufflator. 20 patients will be randomised and assigned to this arm of the trial. Post-op pain outcomes will be compared to the control arm (standard of care), the AirSeal Insufflation System.
Device: surgery
Measuring patient's pain during and after a robotic prostatectomy using the AirSeal® Insufflation System. 20 patients will be randomised and assigned to this arm of the trial. This device is the standard of care at the Lister hospital, Stevenage, UK.
100 patients randomised to two arms will undergo robotic prostatectomies using either the control AirSeal® Insufflation System (AIS) or the intervention Stryker PneumoClear Insufflator. Intra-operative and post-operative pain will be compared between the two arms of the trial.
Also known as: Robotic assisted laparoscopic prostatectomy
Recruitment rates
Time frame: Through study completion estimated to be 6-12 months
Evaluate treatment-based adverse events, serious adverse events, anticipated adverse device effects, unanticipated adverse device effects and all device deficiencies and use errors, regardless of relationship to an adverse event.
Time frame: Through study completion estimated to be 6-12 months
Pre-op vitals
Bloods pressure, heart rate, oxygen saturations, respiration rate, temperature
Time frame: Baseline/day 1
Pre-op BMI (height and weight)
kg/m\^2
Time frame: Baseline/day 1
Pre-op labs
Pre-op FBC, U\&E, CRP and PSA bloods
Time frame: Baseline/day 1
Insufflation Pressure
Intraoperative insufflation pressure (mmHg)
Time frame: Perioperative
Estimated blood loss
Estimated intra-operative blood loss (ml)
Time frame: Perioperative
Blood transfusion
Intra-operative blood transfusions (number of units of blood e.g 0, 1, 2, 3 etc...)
Time frame: Perioperative
Procedure time (initial incision to closure)
Number of minutes from incision to closure
Time frame: Perioperative
Surgeon-determined need to increase IAP beyond "study pressure"
Need to increase insufflation pressure intra-operatively (mmHg)
Time frame: Perioperative
Administration of transversus abdominis plane block
Was a transversus abdominis plane block administered (yes or no)
Time frame: Perioperative
Anesthetic/pain medication administration
Intra-operative administration of analgesia (morphine milligram equivalent units)
Time frame: Perioperative
MedaSense PMD-200 monitor for pain documentation
Intra-operative pain score (NOL score 0-100)
Time frame: Perioperative
Intraoperative Peak Airway Pressure every 15 minutes
Intra-operative PAP (cmH2O)
Time frame: Perioperative
Intraoperative End Tidal Carbon Dioxide (ETCO2) every 15 minutes
Intra-operative ETCO2 (mmHg)
Time frame: Perioperative
Time in recovery room
Number of minutes spent in post-op recovery
Time frame: Perioperative
Post-op pain incidence and severity
Pain measured using visual analogue scale, numerical rating scale and pain incidence and interference surveys. Pain surveys done at 1, 3, 6, 12, 18, 24 hours and day 7 and day 30 post-operation.
Time frame: Day 1-30 post-op/post-intervention
Post-op analgesia usage
Post-op analgesia usage on discharge (morphine milligram equivalent units)
Time frame: Day 1-30 post-op/post-intervention
Post- op labs as per standard of care
FBC, U\&E, CRP
Time frame: Day 1-30 post-op/post-intervention
Vital signs 24 hr
Blood pressure, heart rate, respiration rate, oxygen saturations, temperature
Time frame: Day 1 post-op/post-intervention
Presence or absence of postoperative nausea or vomiting
Presence of nausea/vomiting in the post-op period
Time frame: Day 1 post-op/post-intervention
Length of hospital stay
Duration of hospital admission (hours)
Time frame: Day 1-30 post-op/post-intervention
Any complications that were observed. Post-operative complications through 30 days, reported using Clavien-Dindo Classification, including 30-day mortality
Reporting of post-operative complications
Time frame: Day 1-30 post-op/post-intervention
Return to operating room within 24 hour
Reason for return to the operating room and number of returns to operating room
Time frame: Day 1-30 post-op/post-intervention
Readmission to hospital within 30 days
Reason and number of readmissions to hospital
Time frame: Day 1-30 post-op/post-intervention
All Adverse Events (intra-operative and post-operative through 30 days)
Documented using the "Common Terminology Criteria for Adverse Events" (CTCAE) v5.0
Time frame: Day 1-30 post-op/post-intervention
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2025 to primary completion in Dec 2025, 7 months.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 7 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
East and North Hertfordshire NHS Trust